One Phase 3 test of Auvelity met its main goal in Alzheimer's agitation while the drug's other pivotal trial showed numerical improvement that fell short of statistical significance. Axsome Therapeutics aims to offer an alternative to Rexulti, a Lundbeck and Otsuka Pharmaceutical product that is the only FDA-approved Alzheimer's agitation drug.
December saw a slew of executive hires, promotions, exits and layoffs across the healthcare industry. For example, companies like Humana and Mayo Clinic hired new C-suite leaders, organizations including Atlantic Health System and Amwell are saying goodbye to key executives, and firms like CVS Health and Optum announced rounds of job cuts.
One Phase 3 test of Auvelity met its main goal in Alzheimer's agitation while the drug's other pivotal trial showed numerical improvement that fell short of statistical significance. Axsome Therapeutics aims to offer an alternative to Rexulti, a Lundbeck and Otsuka Pharmaceutical product that is the only FDA-approved Alzheimer's agitation drug.
The Uno Savings Guide is a free resource that helps people check their eligibility for financial benefit programs, like Medicaid, Medicare Savings Programs and SNAP.
Opdivo Qvantig, administered by injection in less than five minutes, is now FDA approved for solid tumor indications covered by Opdivo, a 30-minute intravenous infusion. The new product will help Bristol Myers Squibb compete with biosimilars as Opdivo faces looming patent expiration.
Addressing difficult-to-treat diseases and disorders, quickly, safely, and with little to no side effects is a positive boon to our overburdened health system.
While worries about the affordability of care are sure to persist for many Americans over the coming year, here are some other patient payment trends for providers to watch
In this episode, we're joined by Dr. Piraye Yurttas Beim, founder and CEO of Celmatix, a women's health biotech company.
Celmatix was recentlyawarded$3.5 million from the Advanced Research Projects Agency for Health (ARPA-H) through the Sprint for Women's Health program. In this episode, Beim discusses how Celmatix will be using the funding.
.png)
No comments:
Post a Comment